Biofrontera (BFRI) Expected to Announce Earnings on Thursday

Biofrontera (NASDAQ:BFRI) is projected to issue its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $16.1460 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera Trading Up 0.0%

Biofrontera stock opened at $0.89 on Wednesday. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.19. The company has a market capitalization of $10.36 million, a price-to-earnings ratio of -0.55 and a beta of 0.61. The business’s fifty day simple moving average is $0.87 and its two-hundred day simple moving average is $0.88.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. boosted its holdings in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera accounts for approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. 10.08% of the stock is owned by institutional investors.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.